Ifosfamide - Generic Drug Details

What are the generic drug sources for ifosfamide and what is the scope of patent protection?

Ifosfamide is the generic ingredient in four branded drugs marketed by Baxter Hlthcare, Fresenius Kabi Usa, Hikma, Meitheal, Rising, and Teva Pharms Usa, and is included in seven NDAs. Additional information is available in the individual branded drug profile pages.

There are five drug master file entries for ifosfamide. Five suppliers are listed for this compound.

Summary for ifosfamide

US Patents:	0
Tradenames:	4
Applicants:	6
NDAs:	7
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	130
Clinical Trials:	456
Patent Applications:	4,563
Drug Prices:	Drug price trends for ifosfamide
What excipients (inactive ingredients) are in ifosfamide?	ifosfamide excipients list
DailyMed Link:	ifosfamide at DailyMed

See drug prices for ifosfamide

Recent Clinical Trials for ifosfamide

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
BeBetter Med Inc	Phase 1
Exelixis	Phase 1
Children's Hospital Colorado	Phase 1

See all ifosfamide clinical trials

Pharmacology for ifosfamide

Drug Class	Alkylating Drug
Mechanism of Action	Alkylating Activity

Medical Subject Heading (MeSH) Categories for ifosfamide

Antineoplastic Agents, Alkylating

Anatomical Therapeutic Chemical (ATC) Classes for ifosfamide

L01AA	Nitrogen mustard analogues
L01A	ALKYLATING AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for ifosfamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms Usa	IFOSFAMIDE/MESNA KIT	ifosfamide; mesna	INJECTABLE;INTRAVENOUS	075874-001	Feb 26, 2002		DISCN	No	No
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-004	Oct 10, 1992		DISCN	No	No
Fresenius Kabi Usa	IFOSFAMIDE	ifosfamide	INJECTABLE;INJECTION	090181-001	Sep 22, 2009		DISCN	No	No
Baxter Hlthcare	IFEX/MESNEX KIT	ifosfamide; mesna	INJECTABLE;INJECTION	019763-003	Oct 10, 1992		DISCN	No	No
Fresenius Kabi Usa	IFOSFAMIDE	ifosfamide	INJECTABLE;INJECTION	076078-002	May 28, 2002	AP	RX	No	Yes

Expired US Patents for ifosfamide

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-001	Dec 30, 1988	3,732,340
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988	4,882,452
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-002	Dec 30, 1988	3,732,340
Baxter Hlthcare	IFEX	ifosfamide	INJECTABLE;INJECTION	019763-001	Dec 30, 1988	4,882,452

Ifosfamide Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Ifosfamide

Introduction to Ifosfamide

Ifosfamide, a chemotherapeutic agent with the CAS number 3778-73-2, is widely used in the treatment of various types of cancer, including testicular cancer, ovarian cancer, and some types of lymphoma. Understanding the market dynamics and financial trajectory of ifosfamide is crucial for pharmaceutical companies, healthcare providers, and policymakers.

Market Size and Growth

The ifosfamide market is projected to experience steady growth over the coming years. According to recent market research, the United States and Europe ifosfamide market is expected to reach $321.51 million by 2031, growing at a Compound Annual Growth Rate (CAGR) of 3.78%[1].

Key Market Drivers

Several factors are driving the growth of the ifosfamide market:

Increasing Incidence of Cancer

The rising incidence of cancer globally is a significant driver. As the population ages and lifestyle factors contribute to higher cancer rates, the demand for effective chemotherapeutic agents like ifosfamide increases.

Advancements in Cancer Treatment

Continuous advancements in cancer treatment protocols and the integration of ifosfamide into combination therapies are also boosting market growth.

Government Initiatives and Reimbursement Policies

Government initiatives and reimbursement policies play a crucial role in making ifosfamide more accessible. For instance, changes in payment reform can enhance the affordability and accessibility of cancer treatments, including those involving ifosfamide[2].

Market Challenges

Despite the growth, the ifosfamide market faces several challenges:

Generic Competition

The availability of generic versions of ifosfamide can significantly impact the market. Generic drug companies often offer substantial discounts, which can erode the profits of branded drug manufacturers. For example, generic versions of commonly used medicines can be sold at discounts of 50-70%[3].

Price Sensitivity

The pharmaceutical industry is highly price-sensitive, and the cost of ifosfamide can be a barrier to access. The disparity between the actual cost and the reimbursed price can lead to financial burdens on both taxpayers and consumers.

Regulatory Environment

Regulatory changes and pricing policies can significantly affect the market. For instance, the Pharmaceutical Benefits Scheme (PBS) in Australia sets prices that may not reflect the actual cost of generic drugs, leading to inefficiencies and higher costs for consumers and taxpayers[3].

Financial Trajectory

The financial trajectory of ifosfamide is influenced by several factors:

Revenue Projections

The projected revenue growth indicates a stable financial outlook for the ifosfamide market. The market is expected to grow steadily, driven by increasing demand and advancements in cancer treatment.

Cost and Pricing Dynamics

The cost and pricing dynamics of ifosfamide are complex. While generic versions can be significantly cheaper, the reimbursed prices often do not reflect these discounts. This can lead to substantial profits for pharmacists but increased costs for consumers and taxpayers. For example, in the case of Simvastatin, pharmacists can make a $39.15 profit per pack due to the difference between the actual cost and the reimbursed price[3].

Government Savings and Compensation

Government reforms aimed at reducing costs can impact the financial trajectory. For instance, reforms that aim to reduce the profits made by pharmacists on generic drugs can lead to savings for taxpayers but may also result in increased dispensing fees for pharmacists to ensure their financial sustainability[3].

Impact on Consumers and Taxpayers

The financial dynamics of ifosfamide have significant implications for consumers and taxpayers:

Financial Toxicity

The high cost of cancer treatments, including ifosfamide, can lead to financial toxicity for patients. Early discussions about the financial aspects of care are crucial to mitigate this impact[5].

Taxpayer Burden

The inefficiencies in pricing and reimbursement policies can result in significant taxpayer burdens. For example, the Australian government could save millions of dollars annually by adjusting the reimbursement prices to reflect the actual cost of generic drugs[3].

Key Manufacturer Insights

Leading companies in the ifosfamide market are adopting various strategies to maintain their market position:

Innovation and R&D

Investing in research and development to improve the efficacy and safety of ifosfamide is a key strategy. This includes exploring new indications and combination therapies.

Market Expansion

Expanding into new markets, particularly in regions with growing healthcare needs, is another strategy. This involves navigating local regulatory environments and pricing policies.

Partnerships and Collaborations

Forming partnerships with other pharmaceutical companies, research institutions, and healthcare providers can help in improving market penetration and reducing costs.

Conclusion

The market dynamics and financial trajectory of ifosfamide are shaped by a combination of factors including market growth drivers, challenges, and regulatory environments. Understanding these dynamics is essential for stakeholders to navigate the complexities of the pharmaceutical market and ensure that ifosfamide remains accessible and affordable for those who need it.

Key Takeaways

• The ifosfamide market is projected to grow at a CAGR of 3.78% to reach $321.51 million by 2031.
• Increasing cancer incidence and advancements in cancer treatment are key drivers.
• Generic competition and price sensitivity are significant challenges.
• Regulatory changes and pricing policies can impact the financial trajectory.
• Financial toxicity and taxpayer burden are critical considerations.
• Leading companies are focusing on innovation, market expansion, and partnerships.

FAQs

Q: What is the projected market size of ifosfamide by 2031? A: The ifosfamide market is expected to reach $321.51 million by 2031[1].

Q: What are the main drivers of the ifosfamide market growth? A: The main drivers include the increasing incidence of cancer and advancements in cancer treatment protocols[1].

Q: How does generic competition affect the ifosfamide market? A: Generic competition can significantly reduce the profits of branded drug manufacturers due to substantial discounts offered by generic drug companies[3].

Q: What is the impact of regulatory changes on the ifosfamide market? A: Regulatory changes can affect pricing policies, leading to either savings or increased costs for consumers and taxpayers[3].

Q: How does financial toxicity relate to ifosfamide treatment? A: Financial toxicity refers to the financial burden on patients due to the high cost of cancer treatments, including ifosfamide. Early discussions about financial aspects are crucial to mitigate this impact[5].

Sources

1. Verified Market Research: United States and Europe Ifosfamide (CAS 3778-73-2) Market Size...
2. Pharmacy Times: Payment Reform is Refueling the Wellness Movement: Is This the Solution to Our Sick-Care Problem?
3. Australian Parliament House: Supplementary information from Medicines Australia
4. Wicz: Ifosfamide Market Size 2024: Industry Trends, Revenue Projections and Key Manufacturer Insights to 2032
5. Oncology Nursing News: Financial Toxicity